company-logo

GeNeuro SA, a clinical-stage biopharmaceutical company, develops drugs for the treatment of neurodegenerative and autoimmune diseases. The company's lead therapeutic candidate is temelimab, a monoclonal antibody, which has completed Phase IIb clinical trial for multiple sclerosis; and is in Phase IIa to treat type 1 diabetes, as well as is in Phase I for the treatment of chronic inflammatory demyelinating polyneuropathy. It has cooperative research and development agreements with The National Institute of Neurological Disorders and Stroke to develop novel therapeutic antibodies for the treatment of amyotrophic lateral sclerosis; and Academic labs to develop inflammatory psychosis, as well as a research collaboration agreement with International Center for Infectiology Research; and with Northwestern University for human endogenous retrovirus W envelope protein (HERV-W ENV) in long-haul COVID patients. The company was incorporated in 2006 and is headquartered in Plan-les-Ouates, Switzerland.

GeNeuro Dividend Announcement

GeNeuro does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
Stay tuned for updates on GeNeuro dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.

GeNeuro Dividend History

GeNeuro Dividend Yield

GeNeuro current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing GeNeuro stock? Use our calculator to estimate your expected dividend yield:

GeNeuro Financial Ratios

P/E ratio-0.44
PEG ratio0.00
P/B ratio-0.22
ROE70.94%
Payout ratio0.00%
Current ratio0.37
Quick ratio0.37
Cash Ratio0.29

GeNeuro Dividend FAQ

Does GeNeuro stock pay dividends?
GeNeuro does not currently pay dividends to its shareholders.
Has GeNeuro ever paid a dividend?
No, GeNeuro has no a history of paying dividends to its shareholders. GeNeuro is not known for its dividend payments.
Why doesn't GeNeuro pay dividends?
There are several potential reasons why GeNeuro would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will GeNeuro ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While GeNeuro has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is GeNeuro a dividend aristocrat?
GeNeuro is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is GeNeuro a dividend king?
GeNeuro is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is GeNeuro a dividend stock?
No, GeNeuro is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy GeNeuro stocks?
To buy GeNeuro you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy GeNeuro stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.